Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Silence Therapeutics Promotes Tony Sedgwick To CEO - Quick Facts

Silence Therapeutics plc (SLN.L) announced the promotion of Tony Sedgwick to the role of chief executive from chief business officer, effective immediately, and the departure of Thomas Christély who has resigned as a director of the company for personal reasons but would ensure a smooth transition.

Anthony David Sedgwick, with an extensive experience from European life science companies including over 15 years at Roche, joined Silence in September 2011 to lead a new business development team. Prior to joining Silence, Tony was CEO of Novacta and Chairman of the Norwegian biotech company Plastid AS. Earlier, Tony was also CEO of two acquired companies namely Daniolabs Ltd. and Cambridge Biotechnology Ltd.

Click here to receive FREE breaking news email alerts for Silence Therapeutics and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy. FCA US, until recently known as Chrysler, said Friday it is recalling 257,000 Dodge Ram pickups. The auto maker says the rear axle pinion nut on certain model year 2005 Dodge Ram 1500 trucks may loosen due to an undersized spline on the pinion gear. If the pinion nut loosens, the rear axle may... This medical device company has a very impressive track record of growing business over the past decade. increasing sales from $490.2 million in 2004 to $1.72 billion this year. The Silicone Hydrogel daily disposable lens portfolio constitutes a major avenue for growth.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.